Cargando…
New Therapeutic Options for Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC), one of the most common lethal diseases in the world, has a 5-year survival rate of only 7%. Hepatocellular carcinoma has no symptoms in the early stage but obvious symptoms in the late stage, leading to delayed diagnosis and reduced treatment efficacy. In recent years...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791453/ https://www.ncbi.nlm.nih.gov/pubmed/32799550 http://dx.doi.org/10.1177/1073274820945975 |
_version_ | 1783633607933296640 |
---|---|
author | Ma, Yu-Shui Liu, Ji-Bin Wu, Ting-Miao Fu, Da |
author_facet | Ma, Yu-Shui Liu, Ji-Bin Wu, Ting-Miao Fu, Da |
author_sort | Ma, Yu-Shui |
collection | PubMed |
description | Hepatocellular carcinoma (HCC), one of the most common lethal diseases in the world, has a 5-year survival rate of only 7%. Hepatocellular carcinoma has no symptoms in the early stage but obvious symptoms in the late stage, leading to delayed diagnosis and reduced treatment efficacy. In recent years, as the scope of HCC research has increased in depth, the clinical development and application of molecular targeted drugs and immunotherapy drugs have brought new breakthroughs in HCC treatment. Targeted therapy drugs for HCC have high specificity, allowing them to selectively kill tumor cells and minimize damage to normal tissues. At present, these targeted drugs are mainly classified into 3 categories: small molecule targeted drugs, HCC antigen-specific targeted drugs, and immune checkpoint targeted drugs. This article reviews the latest research progress on the targeted drugs for HCC. |
format | Online Article Text |
id | pubmed-7791453 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-77914532021-01-15 New Therapeutic Options for Advanced Hepatocellular Carcinoma Ma, Yu-Shui Liu, Ji-Bin Wu, Ting-Miao Fu, Da Cancer Control Review Hepatocellular carcinoma (HCC), one of the most common lethal diseases in the world, has a 5-year survival rate of only 7%. Hepatocellular carcinoma has no symptoms in the early stage but obvious symptoms in the late stage, leading to delayed diagnosis and reduced treatment efficacy. In recent years, as the scope of HCC research has increased in depth, the clinical development and application of molecular targeted drugs and immunotherapy drugs have brought new breakthroughs in HCC treatment. Targeted therapy drugs for HCC have high specificity, allowing them to selectively kill tumor cells and minimize damage to normal tissues. At present, these targeted drugs are mainly classified into 3 categories: small molecule targeted drugs, HCC antigen-specific targeted drugs, and immune checkpoint targeted drugs. This article reviews the latest research progress on the targeted drugs for HCC. SAGE Publications 2020-08-17 /pmc/articles/PMC7791453/ /pubmed/32799550 http://dx.doi.org/10.1177/1073274820945975 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Ma, Yu-Shui Liu, Ji-Bin Wu, Ting-Miao Fu, Da New Therapeutic Options for Advanced Hepatocellular Carcinoma |
title | New Therapeutic Options for Advanced Hepatocellular
Carcinoma |
title_full | New Therapeutic Options for Advanced Hepatocellular
Carcinoma |
title_fullStr | New Therapeutic Options for Advanced Hepatocellular
Carcinoma |
title_full_unstemmed | New Therapeutic Options for Advanced Hepatocellular
Carcinoma |
title_short | New Therapeutic Options for Advanced Hepatocellular
Carcinoma |
title_sort | new therapeutic options for advanced hepatocellular
carcinoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791453/ https://www.ncbi.nlm.nih.gov/pubmed/32799550 http://dx.doi.org/10.1177/1073274820945975 |
work_keys_str_mv | AT mayushui newtherapeuticoptionsforadvancedhepatocellularcarcinoma AT liujibin newtherapeuticoptionsforadvancedhepatocellularcarcinoma AT wutingmiao newtherapeuticoptionsforadvancedhepatocellularcarcinoma AT fuda newtherapeuticoptionsforadvancedhepatocellularcarcinoma |